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OBJECTIVES: This research estimates incremental cost-utility
ratios for atorvastatin, simvastatin and pravastatin for treatment
of patients with hypercholesterolemia in secondary prevention
and various age groups. METHODS: By using a Markov model
with ﬁve ﬁnal outcomes, namely angina pectoris (AP), myocar-
dial infarction (MI), cerebrovascular disease (CVD), absence of
cardiovascular events and death, the medical care cost–utility in
the treatment of patients with hypercholesterolemia was esti-
mated. The following age groups were identiﬁed: 41–50 years,
51–60 years, 61–70 years and 71–80 years. The follow-up period
was ten years. A 5% discount rate was used for cost-utility
analysis. The perspective was that of the National Health
System. Quality-adjusted life-year estimates (QALYs) for each
ﬁnal outcome were obtained through a survey among cardiolo-
gists with clinical experience and life extension tables in the lit-
erature. Life years adjusted by life quality were constructed.
Costs per age group and type of event were obtained by review-
ing clinical records. Probabilistic sensitivity analysis was per-
formed and acceptability curves were constructed. RESULTS:
Costs and utilities vary among the various age groups. The
lowest annual average medical care cost per patient corresponds
to patients in the 41–50 year age group (US $33,000), and 
the highest among patients in the 71–80 year age group (US
$101,632). The 41–50 year age group produced 5.8 QALYs
being the highest, and the 71–80 year age group produced the
lowest—an average of 0.5 QALYs. In all age groups, atorvas-
tatin turned out to be the dominant treatment. CONCLUSIONS:
The use of atorvastatin in Mexico is the more cost-utility treat-
ment in patients with hypercholesterolemia in secondary pre-
vention in various age groups, but incremental cost–utility ratios
among older patients are actually the highest.
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OBJECTIVES: To determine the average and incremental cost-
effectiveness of two treatment options, single therapy with 
atorvastatin and dual therapy with atorvastatin plus ezetimibe.
METHODS: Decision analyses were used to construct the deci-
sion trees for the two therapies and three LDL cholesterol goals.
Data came from NHANES III and included patient demographic
variables and patient laboratory values. Analyses were done
from the provider’s perspective for a period of one year.
RESULTS: For the LDL cholesterol goal < 160mg/dl, the average
cost-effectiveness ratios were $959 for single therapy and $1,747
for combination therapy, with an incremental cost-effectiveness
ratio of $88,171. For the LDL cholesterol goal < 130mg/dl, the
average cost-effectiveness ratios were $1383 for single therapy
and $2324 for dual therapy, with an incremental cost effective-
ness ratio of $23,564. In the group with LDL cholesterol goal <
100mg/dl, the average cost-effectiveness ratios were $1195 for
single therapy and $1735 for dual therapy, with an incremental
cost-effectiveness ratio of $5581. All results were robust to wide
variations in costs and probabilities of effectiveness. CONCLU-
SION: There were no signiﬁcant increased beneﬁts to using 
dual therapy among patients with established LDL cholesterol
treatment goals of 160mg/dl and 130mg/dl; therefore, single
therapy with atorvastatin appears to be the dominant strategy.
When the established LDL cholesterol goal is lowered to 
100mg/dl, dual therapy appears to be more cost-effective, and
the increased costs required to achieve an additional successful
outcome with dual therapy may be potentially considered
acceptable for providers.
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While treatment guidelines recommend lowering cholesterol to
target levels appropriate for CHD patients, many remain above
goal on current lipid lowering therapy and hence unable to get
the maximum beneﬁt of cholesterol reduction. For these patients,
a recently published clinical trial showed that ezetimibe co-
administration with existing statin therapy gets 72% of patients
to NCEP II goal versus 19% among patients continuing on exist-
ing therapy. OBJECTIVE: To assess cost effectiveness of 
Ezetimibe 10mg (EZ10) co-administration in CHD patients not
attaining goal (LDL-C > 2.59mmol/dL) while on statin therapy
(atorvastatin, and simvastatin). METHOD: Decision-analytic
model was developed to project lifetime costs and beneﬁts of
lipid therapy. Clinical trial data were used to estimate LDL-C
reductions for different treatment strategies. Effect of lipid reduc-
tions on CHD event rates was estimated using Framingham risk
equations and Hong Kong national statistics on nonCHD-related
mortality. Direct costs of CHD events and prices for lipid low-
ering therapy in Hong Kong were used to project lifetime costs.
The model was run for a population consisting of all patients on
simvastatin and atorvastatin in an observational lipid lowering
treatment study in Hong Kong involving patients initiated on a
statin and had not reached goal at the ﬁrst lipid measurement
after treatment. RESULTS: Mean age of study cohort of 67 CHD
patients was 64.7 (SD10.8) years and 30% were female with
mean LDL-C of 3.23mmol/L and TC of 4.85mmol/L. EZ10 co-
administered with statin compared to statin titration is projected
to increase life expectancy in this patient cohort by 0.45 years
with C/LY of $7387 and C/QALY of $7362. CONCLUSION:
Based on the model, treatment with ezetimibe co-administered
with statin for CHD patients not at goal is a cost-effective alter-
native to statin titration and is well below the $45,000
cost/QALY threshold commonly used in these analyses.
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OBJECTIVE: This economic analysis examined the implications
of using ezetimibe/simvastatin (E/S) as ﬁrst-line cholesterol
therapy compared to usual care with statin monotherapy.
